Fruquintinib (formerly known as HMPL-013; Elunate) is a novel, potent, selective and oral small molecule inhibitor of VEGFR1/2/3 family (IC50s = 33, 0.35, and 35 nM) with strong potency and high selectivity.

SU5208 is a kind of bioactive compound.

Dovitinib (formerly TKI258 and CHIR258) is a potent, orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor with potential anticancer activity.

SU5402 (SU-5402; SU 5402) is a multi-targeted RTK (receptor tyrosine kinase) inhibitor with potential antineoplastic activity.

hVEGF-IN-1 represses human VEGF-A translation and shows antitumor activity.

SKLB1002 (SKLB-1002; SKLB 1002) is a novel, potent and ATP-competitive VEGFR2 (VEGF receptor 2) inhibitor with potential antitumor activity.

AMG-Tie2-1 is an inhibitor of tunica interna endothelial cell kinase 2 (Tie2) and VEGF receptor 2 (VEGFR2).

Lenvatinib mesylate (also known as E-7080, E7080, ER-203492-00; Lenvima), the mesylate salt of lenvatinib, is a multi-targeted and orally bioavailable inhibitor of VEGFR2(KDR)/VEGFR3(Flt-4) approved in 2015 for the treatment of differentiated thyroid cancer.

SU5204 is a novel and potent tyrosine kinase inhibitor.

Semaxanib (also known as SU5416) is a novel, potent and selective VEGFR (Flk-1/KDR) inhibitor with potential anticancer activity.